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Influence of endpoint
definitions on the effect of
empagliflozin on major renal
outcomes in the
EMPEROR-Preserved trial
Large-scale trials have evaluated the effects
of treatments on major renal outcomes, but
the definition of a renal event has varied
from trial to trial. In defining a renal event,
trialists included patients who needed renal
replacement therapy or whose estimated
glomerular filtration rate (eGFR) declined
to <10–15 mL/min/1.73 m2, and they also
included patients who experienced large and
sustained decreases in eGFR from baseline.
Different trials have designated different
threshold values for a critical change in
eGFR — with some trials designating a sus-
tained ≥40% decline and other specifying a
sustained ≥50% decrease. Still others have
required a sustained doubling of serum crea-
tinine, which corresponds to a ≥57% decline
in eGFR.
Two large-scale trials have evaluated the
effect of sodium–glucose co-transporter 2
(SGLT2) inhibitors in patients with heart
failure and a reduced ejection fraction.1 They
reported a favourable effect of dapagliflozin
and empagliflozin on heart failure hospi-
talizations, but the two trials prespecified
different definitions of a major renal event.
Both trials included patients who required
renal replacement therapy or who expe-
rienced a sustained decrease in eGFR to
<10–15 mL/min/1.73 m2. However, the
EMPEROR-Reduced trial also included
patients with a sustained ≥40% decrease in
eGFR, whereas the DAPA-HF investigators
specified a sustained ≥50% decrease in eGFR,
and they also included the occurrence of
renal death.1,2 The definition used by the
DAPA-HF trial was used in a meta-analysis
of the two trials.1 In DAPA-HF, the hazard
ratio for the effect of dapagliflozin using
the meta-analysis renal endpoint was 0.71
[95% confidence interval (CI) 0.44–1.16].1
In EMPEROR-Reduced, the hazard ratio for
the effect of empagliflozin was 0.50 (95% CI
0.32–0.77) using the EMPEROR definition,
and it was 0.52 (95% CI 0.29–0.92) using
the meta-analysis definition.1,2 The use of
different definitions for a renal event did not
influence conclusions concerning a benefit
of empagliflozin on renal outcomes in heart
failure and a reduced ejection fraction.
The EMPEROR-Preserved trial was a large,
international, double-blind and placebo-
controlled trial of empagliflozin in patients
with heart failure and a preserved ejection
fraction. Patients with heart failure and
an ejection fraction >40% were randomly
assigned to placebo or empagliflozin for a
median of 26 months. Empagliflozin reduced
the primary endpoint of cardiovascular
death or heart failure hospitalization by 21%
[hazard ratio 0.79 (95% CI 0.69–0.90)] and
decreased total (first and recurrent) hospi-
talizations for heart failure by 27% [hazard
ratio 0.73 (95% CI 0.61–0.88)].3 When the
influence of baseline ejection fraction on
these results was evaluated according to
prespecified subgroups of 41–49%, 50–59%
and ≥60%, baseline ejection fraction did not
influence the effect of empagliflozin on the
primary endpoint. However, ejection fraction
did influence the effect of empagliflozin on
total hospitalizations for heart failure (P-
trend = 0.008), with an attenuated effect in
patients with an ejection fraction ≥60%.4
In contrast to these favourable effects
of empagliflozin on heart failure outcomes
in EMPEROR-Preserved, empagliflozin did
not exert a favourable effect on major renal
outcomes using the EMPEROR definition,5
which relied on a threshold of a sustained
≥40% decrease in eGFR and did not include
the occurrence of renal death. The hazard
ratio for the effect of empagliflozin on major
renal events was 0.95 (95% CI 0.73–1.24).
The neutral effect of empagliflozin on kidney
outcomes was similarly observed across the
prespecified ejection fraction subgroups of
41–49%, 50–59% and ≥60% (Figure 1).5
Therefore, according to the analyses
that had been prespecified in EMPEROR-
Preserved, we found a striking discordance
between the effect of empagliflozin on heart
failure outcomes and major renal events, both
in the overall population and in prespecified
subgroups. When considering all patients
with an ejection fraction >40%, empagliflozin
reduced heart failure hospitalizations with
no effect on major renal outcomes; when
considering prespecified subgroups, ejection
fraction significantly influenced the effect
of empagliflozin on heart failure admissions
but not on renal events. These discordances
were extraordinarily puzzling, since in prior
large-scale clinical trials, the effect of SGLT2
inhibitors on heart failure and renal outcomes
had consistently tracked together.6,7
To determine if the observed discordances
were related to the definition that we speci-
fied for the identification of a renal event, we
asked if our results would differ if we had pre-
specified the more conventional meta-analysis
criteria for a renal event. Accordingly, we re-
analysed the data from EMPEROR-Preserved
using the meta-analysis definition. The haz-
ard ratio for the effect of empagliflozin
on major renal outcomes for the overall
population was 0.78 (95% CI 0.54–1.13), a
finding similar to that previously reported
with dapagliflozin in patients with a reduced
ejection fraction.1 Additionally, using the
meta-analysis definition, ejection fraction had
a significant influence on the magnitude of the
effect of empagliflozin on kidney outcomes
in EMPEROR-Preserved (P-trend = 0.02)
(Figure 1). In patients with an ejection fraction
of 41–49%, the hazard ratio was 0.41 (95%
CI 0.20–0.85), an effect comparable to that
which we previously reported for patients
with an ejection fraction of ≤40% using the
same endpoint [hazard ratio 0.52 (95% CI
0.29–0.92)]1 — a finding consistent with the
premise that patients with an ejection frac-
tion of 41–49% should be classified as having
heart failure and a reduced ejection fraction.8
In contrast, in patients with an ejection frac-
tion ≥60%, the hazard ratio was 1.24 (95%
CI 0.66–2.33). Accordingly, the influence
of ejection fraction on renal outcomes (P-
trend= 0.02) now closely paralleled the influ-
ence of ejection fraction on heart failure hos-
pitalizations (P-trend = 0.008), noted above.4
Our results indicate that the definition
of a major renal outcome can influence
conclusions concerning the effect of a treat-
ment on the progression of kidney disease in
patients with heart failure. In the EMPEROR-
Preserved trial, we found a discordance
between the effects of empagliflozin on heart
failure hospitalizations and renal outcomes
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Figure 1 Effect of empagliflozin on major renal outcomes in EMPEROR-Preserved, overall and in prespecified ejection fraction subgroups,
using different definitions for a renal event. Shown are prespecified ejection fraction subgroups: >40% to <50%, ≥50% to <60% and ≥60%.
Effect in the overall trial is shown in red, whereas effects in the ejection fraction subgroups are shown in blue. The renal endpoint based on a
≥40% sustained decline in estimated glomerular filtration rate (eGFR) was prespecified in the EMPEROR-Reduced and EMPEROR-Preserved
trials, whereas the renal endpoint based on a ≥50% sustained decline in eGFR and including renal death was prespecified in the DAPA-HF
trial and was used in a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.1 Both endpoints included patients who required chronic
renal replacement therapy or who experienced a sustained decrease in eGFR to <10–15 mL/min/1.73 m2. There were 14 renal deaths (10
on placebo and 4 on empagliflozin). The P-trend test refers to the linear influence of three prespecified ejection fraction subgroups on the
magnitude of the effect of empagliflozin on major renal outcomes. CI, confidence interval.
using the EMPEROR definition of a kidney
event, but we noted a concordance between
the heart failure and renal effects of SGLT2
inhibition (overall and in prespecified sub-
groups) when we used a more conventional
definition, a finding that is closely aligned with
observations of the effects of these drugs in
large-scale trials in type 2 diabetes.6,7 Further
exploration of these findings is warranted.
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